**Table S3.** The effect of clinical parameters on the achievement of clinical remission (DAS28-ESR < 2.6) at week 52 in the ADD-ON group (n = 87).

|  |  |  |  |
| --- | --- | --- | --- |
| 　 | Unadjusted analysis | 　 | Adjusted analysis\* |
| 　 | OR\*\* [95%CI] | p value | ROC-AUC | 　 | OR\*\* [95%CI] | p value | ROC-AUC |
| CRP, mg/dL | 1.137 [0.792-1.632] | 0.50 | 0.524 | 　 | 1.053 [0.700-1.584] | 0.81 | 0.753 |
| IL-6, pg/mL | 0.997 [0.982-1.012] | 0.35 | 0.562 | 　 | 0.994 [0.976-1.012] | 0.47 | 0.763 |
| SAA, g/mL | 1.002 [0.998-1.005] | 0.32 | 0.550 | 　 | 1.001 [0.997-1.006] | 0.48 | 0.750 |
| MMP-3, ng/mL | 0.996 [0.990-1.002] | 0.14 | 0.594 | 　 | 0.996 [0.990-1.003] | 0.20 | 0.759 |
| RF, IU/mL | 0.99991 [0.997-1.003] | 0.96 | 0.505 | 　 | 1.0001 [0.996-1.004] | 0.95 | 0.762 |
| IgG, mg/dL | 1.0003 [0.999-1.002] | 0.74 | 0.498 | 　 | 1.0004 [0.999-1.002] | 0.68 | 0.771 |
| TJC28 | **1.118 [1.011-1.237]** | **0.03** | 0.704 | 　 | **1.179 [1.038-1.340]** | **0.009** | 0.818 |
| SJC28 | 1.145 [0.992-1.322] | 0.07 | 0.694 | 　 | 1.166 [0.989-1.375] | 0.06 | 0.811 |
| ESR, mm/h | 1.016 [0.997-1.035] | 0.11 | 0.655 | 　 | 1.008 [0.987-1.030] | 0.46 | 0.745 |
| PGA, mm | 1.009 [0.984-1.034] | 0.49 | 0.552 | 　 | 1.001 [0.971-1.032] | 0.94 | 0.750 |
| TJC68 | 1.050 [0.983-1.122] | 0.16 | 0.653 | 　 | **1.093 [1.002-1.192]** | **0.045** | 0.792 |
| SJC66 | 1.101 [0.990-1.225] | 0.08 | 0.649 | 　 | 1.125 [0.997-1.271] | 0.06 | 0.810 |
| EGA, mm | 0.996 [0.968-1.025] | 0.79 | 0.503 | 　 | 0.991 [0.957-1.026] | 0.59 | 0.756 |
| VAS Pain, mm | 1.004 [0.979-1.030] | 0.76 | 0.515 | 　 | 0.993 [0.964-1.023] | 0.66 | 0.754 |
| DAS28-ESR | **2.266 [1.239-4.144]** | **0.005** | 0.735 | 　 | **2.366 [1.158-4.833]** | **0.01** | 0.805 |
| CDAI | **1.065 [1.004-1.129]** | **0.04** | 0.688 | 　 | **1.091 [1.012-1.177]** | **0.02** | 0.814 |
| SDAI | **1.067 [1.006-1.131]** | **0.03** | 0.704 | 　 | **1.089 [1.012-1.173]** | **0.02** | 0.816 |

\*: Adjusted for age, gender, height, body weight, body mass index, disease duration, prednisolone dose, and methotrexate dose. \*\*: Represents predictive value for clinical remission at week 24 by decrease of 1.0 unit of each parameter.